Effects of angiotensin (1-7) upon right ventricular function in experimental rat pulmonary embolism

Histology and Histopathology

Volumn 26, Issue 10, 2011, Pages 1287-1294

  Watts, John A ^a   Gellar, Michael A ^a   Stuart, Lori ^a   Obraztsova, Maria ^a   Marchick, Michael R ^a   Kline, Jeffrey A ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Angiotensin (1 7); Angiotensin converting enzyme 2; Pulmonary embolism; Renin angiotensin system; Right ventricle

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG EFFECT; HEART MUSCLE; HEART RIGHT VENTRICLE FUNCTION; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PULMONARY EMBOLISM; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

ANIMALIA; RATTUS;

EID: 80053308283     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Becattini C. and Agnelli G. (2008). Predictors of mortality from pulmonary embolism and their influence on clinical management. Thromb. Haemost. 100, 747-751.
2. Benter I.F., Yousif M.H., Anim J.T., Cojocel C. and Diz D.I. (2006). Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am. J. Physiol. Heart Circ. Physiol. 290, H684-H691.
3. Benter I.F., Yousif M.H., Cojocel C., Al Maghrebi M. and Diz D.I. (2007). Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H666-H672.
4. Benter I.F., Yousif M.H., Dhaunsi G.S., Kaur J., Chappell M.C. and Diz D.I. (2008). Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 28, 25-33.
5. Botelho-Santos G.A., Sampaio W.O., Reudelhuber T.L., Bader M., Campagnole-Santos M.J. and Souza dos Santos R.A. (2007). Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am. J. Physiol. Heart Circ. Physiol. 292, H2485-H2490.
6. Bresser P., Pepke-Zaba J., Jais X., Humbert M. and Hoeper M.M. (2006). Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc. Am. Thorac. Soc. 3, 594-600.
7. Chappell M.C., Iyer S.N., Diz D.I. and Ferrario C.M. (1998). Antihypertensive effects of angiotensin-(1-7). Braz. J. Med. Biol. Res. 31, 1205-1212.
8. Clark M.A., Tallant E.A., Tommasi E., Bosch S. and Diz D.I. (2003). Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J. Cardiovasc. Pharmacol. 41, 276-283.
9. Dartevelle P., Fadel E., Mussot S., Chapelier A., Herve P., de Perrot M., Cerrina J., Ladurie F.L., Lehouerou D., Humbert M., Sitbon O. and Simonneau G. (2004). Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 23, 637-648.
10. Diz D.I. (2008). Future directions in cardiovascular pharmacology: examples from the Renin-Angiotensin system. Mol. Interv. 8, 222-225.
11. Ferrario C.M. and Varagic J. (2010). The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am. J. Physiol. Renal Physiol. 298, F1297-F1305.
12. Ferrario C.M., Ahmad S., Joyner J. and Varagic J. (2010). Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv. Pharmacol. 59, 233.
13. Ferreira A.J. and Raizada M.K. (2008). Are we poised to target ACE2 for the next generation of antihypertensives? J. Mol. Med. 86, 685-690.
14. Gallagher P.E., Chappell M.C., Ferrario C.M. and Tallant E.A. (2006). Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am. J. Physiol. Cell Physiol. 290, C420-246.
15. Gallagher P.E., Ferrario C.M. and Tallant E.A. (2008). Regulation of ACE2 in cardiac myocytes and fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 295, H2373-H2379.
16. Giani J.F., Gironacci M.M., Munoz M.C., Pena C., Turyn D. and Dominici F.P. (2007). Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am. J. Physiol. Heart Circ. Physiol. 293, H1154-H1163.
17. Imai Y., Kuba K. and Penninger J.M. (2008). The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp. Physiol. 93, 543-548.
18. Jones A.E., Watts J.A., Debelak J.P., Thornton L.R., Younger J.G. and Kline J.A. (2003). Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat. Am. J. Physiol. Lung Cell. Mol. Physiol. 284, L1072-L1081.
19. Kline J.A., Hernandez-Nino J., Rose G.A., Norton H.J. and Camargo C.A. Jr (2006). Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit. Care Med. 34, 2773-2780.
20. Koka V., Huang X.R., Chung A.C., Wang W., Truong L.D. and Lan H.Y. (2008). Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am. J. Pathol. 172, 1174-1183.
21. Kreit J.W. (2004). The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 125, 1539-1545.
22. Kucharewicz I., Pawlak R., Matys T., Chabielska E. and Buczko W. (2002). Angiotensin-(1-7): an active member of the renin-angiotensin system. J. Physiol. Pharmacol. 53, 533-540.
23. Menon J., Soto-Pantoja D.R., Callahan M.F., Cline J.M., Ferrario C.M., Tallant E.A. and Gallagher P.E. (2007). Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 67, 2809-2815.
24. Petty W.J., Miller A.A., McCoy T.P., Gallagher P.E., Tallant E.A. and Torti F.M. (2009). Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin. Cancer Res. 15, 7398-7404.
25. Piazza G. and Goldhaber S.Z. (2006). Acute pulmonary embolism: part I: epidemiology and diagnosis. Circulation 114, e28-e32.
26. Reudelhuber T.L. (2005). The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Curr. Opin. Nephrol. Hypertens. 14, 155-159.
27. Reudelhuber T.L. (2006). A place in our hearts for the lowly angiotensin 1-7 peptide?. Hypertension 47, 811-815.
28. Sampaio W.O., Nascimento A.A. and Santos R.A. (2003). Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am. J. Physiol. Heart Circ. Physiol. 284, H1985-H1994.
29. Sampaio W.O., Souza dos Santos R.A., Faria-Silva R., Mata Machado L.T., Schiffrin E.L. and Touyz R.M. (2007). Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49, 185-192.
30. Santos R.A., Ferreira A.J. and Simões e Silva A.C. (2008). Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp. Physiol. 93, 519-527.
31. Schoepf U.J., Kucher N., Kipfmueller F., Quiroz R., Costello P. and Goldhaber S.Z. (2004). Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 110, 3276-3280.
32. Stein P.D., Hull R.D., Ghali W.A., Patel K.C., Olson R.E., Meyers F.A. and Kalra N.K. (2003). Tracking the uptake of evidence: two decades of hospital practice trends for diagnosing deep vein thrombosis and pulmonary embolism. Arch. Intern. Med. 163, 1213-1219.
33. Stevinson B.G., Hernandez-Nino J., Rose G. and Kline J.A. (2007). Echocardiographic and functional cardiopulmonary problems six months after first-time pulmonary embolism in previously healthy patients. Eur. Heart J. 28, 2517-2524.
34. Stewart J.A. Jr, Lazartigues E. and Lucchesi P.A. (2008). The angiotensin converting enzyme 2/Ang-(1-7) axis in the heart: a role for MAS communication? Circ. Res. 103:1197-1199.
35. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V. and Egido J. (2003). Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35, 881-900.
36. Tapson V.F. (2008). Acute pulmonary embolism. N. Engl. J. Med. 358, 1037-1052.
37. Ten Wolde M., Sohne M., Quak E., Mac Gillavry M.R. and Buller H.R. (2004). Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch. Intern. Med. 164, 1685-1689.
38. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galie N., Pruszczyk P., Bengel F., Brady A.J., Ferreira D., Janssens U., Klepetko W., Mayer E., Remy-Jardin M., Bassand J.P., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Zamorano J.L., Andreotti F., Ascherman M., Athanassopoulos G., De Sutter J., Fitzmaurice D., Forster T., Heras M., Jondeau G., Kjeldsen K., Knuuti J., Lang I., Lenzen M., Lopez-Sendon J., Nihoyannopoulos P., Perez Isla L., Schwehr U., Torraca L., Vachiery J.L. and Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (2008). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 29, 2276-2315.
39. Varagic J., Trask A.J., Jessup J.A., Chappell M.C. and Ferrario C.M. (2008). New angiotensins. J. Mol. Med. 86, 663-671.
40. Watts J.A., Zagorski J., Gellar M.A., Stevinson B.G. and Kline J.A. (2006). Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J. Mol. Cell. Cardiol. 41, 296-307.
41. Watts J.A., Gellar M.A., Obraztsova M., Kline J.A. and Zagorski J. (2008). Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int. J. Exp. Pathol. 89, 389-399.
42. Watts J.A., Gellar M.A., Stuart L., Obraztsova M. and Kline J.A. (2009). Proinflammatory events in right ventricular damage during pulmonary embolism: Effects of treatment with Ketorolac in rats. J. Cardiovasc. Pharmacol. 54, 252.
43. Watts J.A., Marchick M.R. and Kline J.A. (2010). Right ventricular heart failure from pulmonary embolism: key distinctions from chronic pulmonary hypertension. J. Card. Fail. 16, 250-259.
44. Zagorski J., Debelak J., Gellar M., Watts J.A. and Kline J.A. (2003). Chemokines accumulate in the lungs of rats with severe pulmonary embolism induced by polystyrene microspheres. J. Immunol. 171, 5529-5536.
45. Zagorski J., Gellar M.A., Obraztsova M., Kline J.A. and Watts J.A. (2007). Inhibition of CINC-1 decreases right ventricular damage caused by experimental pulmonary embolism in rats. J. Immunol. 179, 7820-7826.
46. Zagorski J., Obraztsova M., Gellar M.A., Kline J.A. and Watts J.A. (2009). Transcriptional changes in right ventricular tissues are enriched in the outflow tract compared with the apex during chronic pulmonary embolism in rats. Physiol. Genomics 39, 61-71.
47. Zagorski J., Sanapareddy N., Gellar M.A., Kline J.A. and Watts J.A. (2008). Transcriptional profile of right ventricular tissue during acute pulmonary embolism in rats. Physiol. Genomics 34, 101-111.
48. Zhang R., Wu Y., Zhao M., Liu C., Zhou L., Shen S., Liao S., Yang K., Li Q. and Wan H. (2009). Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L631-L640.